Novartis pediatric psoriasis treatment Cosentyx approved in China

This approval in China follows recent approval of Cosentyx in the United States and Europe for the treatment of moderate-to-severe plaque psoriasis in pediatric patients six years and older who are candidates for systemic therapy or phototherapy.

"Novartis is committed to making Cosentyx available to young patients who may benefit from the therapy and has recently filed for US and European regulatory approval for Cosentyx as a potential treatment in juvenile psoriatic arthritis (JPsA) and enthesitis-related arthritis (ERA), two subtypes of juvenile idiopathic arthritis (JIA)," the release stated.

Currently, there are very limited approved treatment options for JIA, and only a minority of patients go on to achieve and maintain an inactive disease state.

Cosentyx is backed by more than 14 years of clinical experience and long-term five-year clinical data across three indications of psoriasis, psoriatic arthritis (PsA) and axial spondyloarthritis (AS), as well as real-world evidence. These data strengthen the unique position of Cosentyx as a rapid and long-lasting comprehensive treatment across AS, PsA and psoriatic disease, with more than 500,000 patients treated worldwide with Cosentyx since launch.